Alkermes to Report Second Quarter Financial Results on July 29, 2025
Alkermes (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has scheduled its second quarter 2025 financial results conference call and webcast for July 29, 2025, at 8:00 a.m. ET.
The company specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains operations across Ireland, Massachusetts, and Ohio.
Alkermes (Nasdaq: ALKS), un'azienda biofarmaceutica globale specializzata in neuroscienze, ha programmato la conferenza telefonica e la webcast per la presentazione dei risultati finanziari del secondo trimestre 2025 per il 29 luglio 2025 alle 8:00 ET.
L'azienda si dedica allo sviluppo di terapie per la dipendenza da alcol, dipendenza da oppioidi, schizofrenia e disturbo bipolare di tipo I. Il loro portafoglio comprende candidati clinici e preclinici per disturbi neurologici come la narcolessia e l'ipersonnia idiopatica. Alkermes opera in Irlanda, Massachusetts e Ohio.
Alkermes (Nasdaq: ALKS), una compañía biofarmacéutica global enfocada en neurociencia, ha programado su llamada de conferencia y webcast para los resultados financieros del segundo trimestre de 2025 para el 29 de julio de 2025 a las 8:00 a.m. ET.
La empresa se especializa en desarrollar tratamientos para la dependencia del alcohol, dependencia de opioides, esquizofrenia y trastorno bipolar I. Su cartera incluye candidatos clínicos y preclínicos para trastornos neurológicos como la narcolepsia y la hipersomnia idiopática. Alkermes mantiene operaciones en Irlanda, Massachusetts y Ohio.
Alkermes (나스닥: ALKS)는 신경과학에 중점을 둔 글로벌 바이오제약 회사로, 2025년 2분기 재무 실적 컨퍼런스 콜과 웹캐스트를 2025년 7월 29일 오전 8시(동부시간)에 예정하고 있습니다.
이 회사는 알코올 의존증, 오피오이드 의존증, 정신분열증, 양극성 장애 I형 치료제 개발에 특화되어 있습니다. 또한 기면증과 특발성 과다수면증 같은 신경학적 질환에 대한 임상 및 전임상 후보물질도 보유하고 있습니다. Alkermes는 아일랜드, 매사추세츠, 오하이오에서 운영되고 있습니다.
Alkermes (Nasdaq : ALKS), une entreprise biopharmaceutique mondiale spécialisée en neurosciences, a programmé sa conférence téléphonique et webcast pour les résultats financiers du deuxième trimestre 2025 le 29 juillet 2025 à 8h00 ET.
La société se concentre sur le développement de traitements pour la dépendance à l'alcool, la dépendance aux opioïdes, la schizophrénie et le trouble bipolaire de type I. Son portefeuille comprend des candidats cliniques et précliniques pour des troubles neurologiques tels que la narcolepsie et l'hypersomnie idiopathique. Alkermes opère en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes (Nasdaq: ALKS), ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, hat seine Telefonkonferenz und Webcast zur Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 29. Juli 2025 um 8:00 Uhr ET angesetzt.
Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen für Alkoholabhängigkeit, Opioidabhängigkeit, Schizophrenie und bipolare Störung Typ I. Die Pipeline umfasst klinische und präklinische Kandidaten für neurologische Erkrankungen wie Narkolepsie und idiopathische Hypersomnie. Alkermes ist in Irland, Massachusetts und Ohio tätig.
- None.
- None.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-second-quarter-financial-results-on-july-29-2025-302505916.html
SOURCE Alkermes plc
FAQ
When will Alkermes (ALKS) report Q2 2025 earnings?
How can investors access Alkermes' Q2 2025 earnings call?
What therapeutic areas does Alkermes (ALKS) focus on?
Where are Alkermes' main operations located?
